8.27
-0.41(-4.72%)
Currency In USD
| Previous Close | 8.68 |
| Open | 8.81 |
| Day High | 9.06 |
| Day Low | 8.27 |
| 52-Week High | 17.4 |
| 52-Week Low | 5 |
| Volume | 37,713 |
| Average Volume | 17,515 |
| Market Cap | 10.43M |
| PE | -0.39 |
| EPS | -21.29 |
| Moving Average 50 Days | 7.83 |
| Moving Average 200 Days | 8.65 |
| Change | -0.41 |
If you invested $1000 in Sensei Biotherapeutics, Inc. (SNSE) since IPO date, it would be worth $21.88 as of August 18, 2025 at a share price of $8.27. Whereas If you bought $1000 worth of Sensei Biotherapeutics, Inc. (SNSE) shares 3 years ago, it would be worth $200.73 as of August 18, 2025 at a share price of $8.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
GlobeNewswire Inc.
Jul 30, 2025 11:30 AM GMT
BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clini
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split
GlobeNewswire Inc.
Jun 13, 2025 11:30 AM GMT
BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
GlobeNewswire Inc.
May 06, 2025 11:30 AM GMT
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutic